48th week of 2011 patent applcation highlights part 40 |
Patent application number | Title | Published |
20110293542 | ANTIBACTERIAL AGENT COMPOSITION AND ANTIVIRAL AGENT COMPOSITION COMPRISING SILICON-CONTAINING COMPOUND; ANTIBACTERIALIZING METHOD, CLEANING/MOUTH RINSING METHOD; METHOD FOR FIXING ANTIBACTERIAL AGENT AND ANTIVIRAL AGENT - Disclosed is an antibacterial agent composition which is highly safe and has excellent antibacterial abilities, by using a silicon-containing compound that is obtained by a specific manufacturing method. The antibacterial agent composition has a more stable antibacterial component, and is capable of imparting antibacterial abilities to teeth, while being also capable of cleaning an article or the mouth. Also disclosed are: an antiviral agent composition which is highly safe and has excellent virus deactivation abilities; an antibacterializing method, a cleaning/mouth rinsing method, each using the antibacterial agent composition or the antiviral agent composition; and a method for fixing an antibacterial agent or an antiviral agent. The antibacterial agent composition may contain a silicon-containing compound which is represented by general formula (1) and obtained by reacting a specific triethoxysilyl compound in an ethanol solvent. | 2011-12-01 |
20110293543 | ANHYDROUS COMPOSITION COMPRISING A DIBENZOYLMETHANE COMPOUND AND A COLOR PIGMENT - The invention relates to an anhydrous color cosmetic composition including a cosmetically-acceptable hydrophobic vehicle that includes a wax component, an oil component, and an organic UV filter component that includes a dibenzoylmethane compound. The composition also includes a powder component that includes a color pigment and an oil-absorbing powder. | 2011-12-01 |
20110293544 | HIGH UNSAPONIFIABLES AND METHODS OF USING THE SAME - Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. Properties that are sought in traditional saponification of natural oils are a result of low levels of unsaponifiables. These properties include high levels of aqueous surfactant activity, water-solubility or ready water-dispersability, activity as foaming agents, and the like. An objective of traditional saponification processes is to increase the water-solubility and surfactant activity of naturally occurring materials. It has been found that the application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6% by total weight of the material), produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6% by weight of unsaponifiables. The resulting hydrolysates from the practice of the present invention are substantive, resisting both physical and aqueous-based removal from skin and hair, exhibit a very unique surfactant property, and are not foaming agents with water. Hydrolysates according to the present invention may thus be used to enhance the performance of cosmetics and pharmaceuticals. These hydrolysates can be are bioactive agents and alternative natural carrying agents for topical application of materials, particularly for application of materials to the skin or hair of subjects, and provide a substantive support for the materials carried. | 2011-12-01 |
20110293545 | Dolichos Biflorus Extract For Use In Cosmetic Skin Treatment - The present invention pertains to a | 2011-12-01 |
20110293546 | ANTIBACTERIAL ARTIFICIAL NAIL COMPOSITION - The present invention provides an antibacterial artificial nail composition which can form a cured article having an antibacterial effect by applying the composition on a surface of a natural nail or an artificial nail and polymerizing the composition, using an artificial nail technique of forming a cured article on a natural nail or an artificial nail. | 2011-12-01 |
20110293547 | PVD METAL EFFECT PIGMENT HAVING GRADIENT ON NANOSCALE METAL PARTICLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF - A platelet-shaped PVD metallic effect pigment having first and second outer faces, the platelet-shaped PVD metallic effect pigment having at least one PVD layer, the at least one PVD layer including elemental metal with clusters of elemental metal and metal oxide. The amounts of elemental metal in the first outer face and in the second outer face of the PVD metallic effect pigment are different from one another and they differ by at least 10 atom %. The disclosure further relates to a method for producing these platelet-shaped PVD metallic effect pigments, and to their use. | 2011-12-01 |
20110293548 | Solid, Compact Powder Cosmetic Product and Process for Obtaining the Same - The present invention provides a solid cosmetic product consisting of a substantially anhydrous, compact cosmetic powder comprising, as essential ingredients, one or more thermoreversible polysaccharides, one or more humectants, one or more emollients and a powder phase, and also optionally conventional cosmetic ingredients. The present invention further provides a process for obtaining such a solid, compact powder cosmetic product, which comprises the steps of making an aqueous paste using the essential ingredients and optionally conventional cosmetic ingredients, allowing the paste to solidify, and then subjecting the solidified paste to a heat treatment for removing water from the solidified paste. | 2011-12-01 |
20110293549 | COMPOSITION, METHOD AND KIT FOR ENHANCING HAIR - Compositions for application and methods of application of a composition to modify hair. In one embodiment, a composition includes a compound (molecule) represented by: | 2011-12-01 |
20110293550 | LONG-WEAR, WATERPROOF AND WASHABLE MASCARA COMPOSITION - The present invention is directed to long wear, washable and waterproof eye makeup composition having a unique texture and feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) at least one oil-soluble high carbon polar modified polymer; (d) water; (e) optionally, at least one non-volatile oil capable of solubilizing the polar modified polymers; (d) optionally, at least one volatile solvent; (e) optionally, at least one colorant; and (f) optionally, at least one high-temperature melting wax. | 2011-12-01 |
20110293551 | WATER-IN-OIL EMULSION COMPOSITION FOR HAIR - Present invention is related to conditioning composition for hair especially suited for leave-in application in water-in-oil (W/O) emulsion form. The object of the present invention is water in oil emulsion composition for hair comprising at least one oil, at least one silicone surfactant. at least one alkoxylated and hydroxylated amino silicone and water. | 2011-12-01 |
20110293552 | HAIR CARE COMPOSITION COMPRISING A DENDRITIC MACROMOLECULE - Hair care composition comprising an emulsified hydrophobically functionalised dendritic macromolecule. | 2011-12-01 |
20110293553 | IDENTIFICATION OF INSECT ATTRACTANT, ARRESTING, AND/OR AGGREGATION COMPOUNDS AND METHODS THEREOF - Compounds, compositions, kits, devices, and methods of attracting, detecting, eradicating, controlling, or killing an insect, such as a bed bug, by utilizing insect attractant, arresting, and/or aggregation compounds and compositions is provided. Insect attractant, arresting, and/or aggregation compounds identified from insect fecal extract by an analytical technique, such as gas chromatography, nuclear magnetic resonance (NMR), Carbon-13 NMR, mass spectroscopy, LC-MS, GC-MS, high performance liquid chromatography (HPLC), or combinations thereof are provided. A bed bug attractant, arresting, and/or aggregation compound identified from bed bug feces and exhibiting a Carbon-13 NMR peak at about δ 159.453 ppm is also provided. | 2011-12-01 |
20110293554 | RECOMBINANT HUMAN G-CSF DIMER AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES - This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased. | 2011-12-01 |
20110293555 | TUMOR NECROSIS FACTOR-ALPHA MUTANTS - The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient. | 2011-12-01 |
20110293556 | TREATMENT OF INSULIN RESISTANCE/METABOLIC SYNDROME TO ALLEVIATE THE RISKS OF DEMENTIA - This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with β-amyloid protein for the TDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals. | 2011-12-01 |
20110293557 | CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS - The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the ApoA molecule. | 2011-12-01 |
20110293558 | MATERIAL PROPERTIES OF T CELLS AND RELATED METHODS AND COMPOSITIONS - The invention in some aspects relates to methods, devices and compositions for evaluating material properties, such as mechanical and rheological properties of substances, particularly biological substances, such as cells, tissues, and biological fluids. In some aspects, the invention relates to methods, devices and compositions for evaluating material properties of deformable objects, such as cells. In further aspects, the invention relates to methods, devices and compositions for diagnosing and/or characterizing disease based on material properties of biological cells. | 2011-12-01 |
20110293559 | CATABOLIC AGENTS - This invention relates to the use of agents which are capable of the catabolism of components of cartilage extracellular matrix to promote cartilage regeneration within cartilage pathologies and to promote cartilage integration within focal defects. | 2011-12-01 |
20110293560 | METHOD FOR DETERMINING IMMUNE SYSTEM ACTIVITY AND MEDICAMENT FOR INFLUENCING SAME - A method for the determination of the state of the immune system, e.g. the state of activity and activation, respectively, of the immune system, using the determination of presence of a blood or peripheral mononuclear cell or plasma marker. The marker can be determined directly, e.g. by determination of its titre using a specific antibody against the marker, or indirectly, e.g. by the determination of the mRNA encoding the marker. Further, the invention relates to the use of the protein corresponding to the marker analysed in the analytical method, as a medicament, especially for influencing, e.g. for activating the immune system, more specifically for activating the cytotoxicity of NK cells as well as for activating the cytotoxicity and the proliferation of T-cells. | 2011-12-01 |
20110293561 | ANTI-KIR COMBINATION TREATMENTS AND METHODS - Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided. | 2011-12-01 |
20110293562 | USE OF CARDIOTROPHIN-1 FOR THE TREATMENT OF METABOLIC DISEASES - The invention is related to the use of cardiotrophin-1 (CT-1) for the treatment of obesity and associated disorders: hyperglycaemias, insulin resistance, development of type 2 diabetes and dyslipemias and given its anorexigenic role, fat oxidation stimulant, hypoglycaemic, sensitizing agent of the action of insulin on a skeletal muscle level and inhibitor of the intestinal transport of glucose by enterocytes. | 2011-12-01 |
20110293563 | 1'SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 2011-12-01 |
20110293564 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES - This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other deseases like cancers. | 2011-12-01 |
20110293565 | NOVEL SYNTHETIC AGONISTS OF TLR9 - The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles. | 2011-12-01 |
20110293566 | DIFFOCIN AND METHODS OF USE THEREOF - This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill | 2011-12-01 |
20110293567 | USE OF BACTERIA FOR THE SENSING AND KILLING OF CANCER CELLS - The present invention relates to the field of cancer therapy. Specifically, a chemotaxis fusion-receptor that directs bacteria towards tumors is disclosed. Further encompassed by the present invention is a bacterial cell that comprises at least one chemotaxis fusion-receptor and, preferably, a killing module for the destruction of tumor cells. | 2011-12-01 |
20110293568 | LACTOBACILLUS HELVETICUS CNCM I-4095 AND WEIGHT CONTROL - The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of | 2011-12-01 |
20110293569 | LACTOBACILLUS RHAMNOSUS CNCM I-4096 AND WEIGHT CONTROL - The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of | 2011-12-01 |
20110293570 | ISOLATION OF NOVEL BACTERIA CONTRIBUTING TO SOILBORNE DISEASE SUPPRESSION - Embodiments relate to plant disease suppressive microorganisms and compositions including the same, methods for isolating disease suppressive microorganisms, and methods for controlling plant diseases using disclosed compositions and microorganisms. | 2011-12-01 |
20110293571 | METHOD FOR VECTOR DELIVERY - Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract. | 2011-12-01 |
20110293572 | INCREASING THE PLASTICITY OF STEM CELLS - The invention relates to methods of culturing non-embryonic cells to increase their plasticity and their potential to differentiate into multi-lineage cell types. | 2011-12-01 |
20110293573 | METHOD AND APPARATUS FOR CULTURING TISSUE - A method for culturing microtissue is provided. The method includes steps of: (a) forming a pattern microarray on a hydrophobic film; (b) adhering the hydrophobic film to a carrier; (c) disposing a plurality of cells on the hydrophobic film for culturing depending on the pattern microarray, and forming a plurality of hair follicle microtissues. | 2011-12-01 |
20110293574 | Hematopoietic stem cell growth factor - The present invention relates, in general, to stem cells and, in particular, to a hematopoietic stem cell (HSC) growth factor and to methods of using same. | 2011-12-01 |
20110293575 | PHOTOCHEMICAL INTERNALISATION OF KINASE INHIBITORS - The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect. | 2011-12-01 |
20110293576 | MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF ISOLATING AND USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders. | 2011-12-01 |
20110293577 | Therapeutic Methods Using Adipose Tissue-Derived Cell Suspensions Comprising Adipocytes - Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation of pain associated with an inflammatory disorder in a mammalian subject. Also provided herein is a method of treating an inflammatory disorder, a cartilage or bone disorder or alleviating pain associated with an inflammatory disorder in a mammalian subject, comprising administering to the subject a pharmaceutical composition which comprises: (i) an adipose tissue-derived cell suspension which comprises adipocytes; or (ii) a cell-free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes, together with a pharmaceutically-acceptable carrier or diluent. | 2011-12-01 |
20110293578 | Use of Stem Cells to Prevent Neuronal Dieback - The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons. | 2011-12-01 |
20110293579 | Bi-specific fusion proteins - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration. | 2011-12-01 |
20110293580 | GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES - Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs. | 2011-12-01 |
20110293581 | BONE-REGENERATING COMPOSITION CONTAINING ANGIOGENIN - The present invention relates to a bone-regenerating composition containing angiogenin and to a bone-generating scaffold comprising the composition. Angiogenin has a superior ability to induce initial angiogenesis and bone regeneration as compared to the platelet rich plasma (PRP) which is used as a conventional element for stimulating bone regeneration, thus improving the speed of bone regeneration | 2011-12-01 |
20110293582 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 2011-12-01 |
20110293583 | METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described. | 2011-12-01 |
20110293584 | Tissue Regeneration - The present invention relates to a method of treating a tissue defect in a human or animal body comprising the steps of implanting into said body an unseeded scaffold; allowing or effecting a wound healing response at the site of said defect; allowing said scaffold to be vascularized until a substantially sufficient fluid flow through said scaffold is assured for the transport of nutrients and/or waste products, and seeding said vascularised scaffold with a suitable population of tissue-regenerating cells. | 2011-12-01 |
20110293585 | COMPOSITIONS AND METHODS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS - Compositions and methods for treating lysosomal storage diseases are disclosed. Lysosomal dysfunction is usually the result of deficiency of a single enzyme necessary for the metabolism of lipids, glycoproteins (sugar containing proteins) or mucopolysaccharides which are fated for breakdown or recycling. The compositions contain triplex-forming molecules which can be used to induce site-specific homologous recombination in mammalian cells when combined with donor DNA molecules, by stimulating cellular DNA synthesis, recombination, and repair mechanisms. The methods are particular useful for correcting point mutations in genes associated with lysosomal storage diseases such as Gaucher's disease, Fabry disease, and Hurler syndrome. Methods for determining the frequency of target gene repair and assessing the restoration of the enzymatic activity of corrected polypeptides are also disclosed. Ex vivo and in vivo methods of gene correction in patients are also provided. | 2011-12-01 |
20110293586 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2011-12-01 |
20110293587 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2011-12-01 |
20110293588 | METABOLIC UNCOUPLING THERAPY - A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain. | 2011-12-01 |
20110293589 | METHOD OF TREATING VITAMIN B12 DEFICIENCY - A novel method and composition for treating vitamin B | 2011-12-01 |
20110293590 | PHARMACEUTICAL PREPARATION - The pharmaceutical preparation for the treatment of pancreatic insufficiency comprises a liquid administering form of enzymes. | 2011-12-01 |
20110293591 | Composition - The present invention provides a composition, and a process for preparing and method for using such a composition. The composition comprises (i) a surface coating material; and (ii) (ii) a cross-linked enzyme crystal or cross-linked enzyme aggregate wherein the enzyme is cross-linked with a multifunctional cross-linking agent and wherein the cross-linked enzyme crystal or cross-linked enzyme aggregate has an antifouling activity or generates an antifouling compound. Suitably the composition may be used to inhibit biofilm formation. | 2011-12-01 |
20110293592 | METHOD OF TREATING CORONARY ARTERIES WITH PERIVASCULAR DELIVERY OF THERAPEUTIC AGENTS - A method of treating the intraluminal disease in a coronary artery by injecting therapeutic agents perivascularly into the myocardium near the site of disease. | 2011-12-01 |
20110293593 | SIVA 2 STABILIZATION - The present invention relates to modulation of SIVA2 stability by N-acetylglucosamine, phosphorylation of ubiquitination in treatment or prevention of diseases, disorders or conditions. | 2011-12-01 |
20110293594 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 2011-12-01 |
20110293595 | Prophylactic and therapeutic treatment of Alzheimer's Disease, neuro-degenerative diseases, protein aggregation diseases, Parkinson's Disease and amyloid diseases, using phytic acid and phytate - A composition and method for the treatment of Alzheimer's Disease, and/or related protein aggregation diseases and/or amyloidoses and/or a neuro-degenerative disease, and/or Parkinson's Disease and/or Parkinsonism including an effective amount of a compound selected from the group consisting of phytic acid (inositol hexakisphosphate), a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams at least once a week up to once per day, with or without a dephosphorylating enzyme. The dosage may be proportionately or disproportionately divided so that the dosage is administered in proportionally or disproportionately reduced amounts which cumulatively add up to a predetermined dosage, in a time period where the proportionately or disproportionately divided dosages are cumulatively equivalent in quantity to the dosage. | 2011-12-01 |
20110293596 | DISEASE CONTROL WITH TICK PHOSPHOLIPASE A2 - The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from | 2011-12-01 |
20110293597 | SERINE PROTEASE DERIVATIVES AND USES IN THE PREVENTION OR THE TREATMENT OF BLOOD COAGULATION DISORDERS - The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders. | 2011-12-01 |
20110293598 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 2011-12-01 |
20110293599 | METHOD FOR MODULATING MUSCLE DIFFERENTIATION OR REGENERATION - Present invention relates to method for promoting or inhibiting muscle differentiation or regeneration using an enhancer or an inhibitor capable of modulating the binding of TAZ polypeptide with MyoD polypeptide; method for screening a substance capable of up- or down-regulating muscle differentiation or regeneration by use of interaction between TAZ polypeptide and MyoD polypeptide; an isolated peptide consisting of an amino acid sequence of SEQ ID NO. 2 which binds to and activates the MyoD polypeptide; a polynucleotide encoding the isolated peptide; and a pharmaceutical composition comprising the isolated peptide or the polynucleotide. | 2011-12-01 |
20110293600 | Anticancer Composition Comprising Antitumor Agent and Substance Having Inhibitory Effects on L1CAM Activity and Expression - The present invention relates to an anticancer composition comprising an antitumor agent as well as a substance having inhibitory effects on the activity or expression of L1CAM; more particularly, to an anticancer composition, which comprises an anti-L1CAM antibody specific to L1CAM, serving as a substance for inhibiting the activity of L1CAM; an oligonucleotide inhibiting the generation of L1CAM, serving as a substance for inhibiting the expression of L1CAM; and a substance selected from cisplatin, gemcitabine, 5-fluorouracil and taxol, serving as an antitumor agent. The composition according to the present invention has the benefit of the combined use of a substance having inhibitory effects on the activity or an expression of L1CAM and an antitumor agent concurrently, separately or sequentially so that it demonstrates stronger and more significant pharmaceutical effects than the exclusive use of those substances on inhibiting proliferation and inducing apoptosis in cancer cells, thereby making it very useful for cancer treatment. | 2011-12-01 |
20110293601 | COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE - The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression. | 2011-12-01 |
20110293602 | VEGF-LIKE FACTOR ANTIBODIES AND METHODS OF USE THEREOF - A novel human gene having a significant homology with a VEGF-C gene, a member of the VEGF family, has been isolated by the PCR method using primers designed based on the sequence of EST that is assumed to be homologous with the C-terminal region of the VEGF-C gene. Mouse and rat genes have been isolated based on the human gene isolated as above. A protein encoded by the above human gene has been isolated by introducing the gene into | 2011-12-01 |
20110293603 | AMINO ACID SEQUENCES DIRECTED AGAINST MULTITARGET SCAVENGER RECEPTORS AND POLYPEPTIDES - The present invention relates to amino acid sequences that are directed against (as defined herein) multitarget scavenger receptors such as e.g. Lox-1, RAGE, CD36, SR-A1, SR-B1, galectin-1, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). | 2011-12-01 |
20110293604 | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN THE PROCESS OF BONE REMODELING - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes. | 2011-12-01 |
20110293605 | ANTIBODY FORMULATION - Herein described are liquid formulations of antibodies and biologically active fragments thereof that specifically bind to a human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution. | 2011-12-01 |
20110293606 | ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND VINCRISTINE - Pharmaceutical composition comprising an antibody specifically recognizing CD38 and vincristine. | 2011-12-01 |
20110293607 | Antibody Variants Having Modifications In The Constant Region - The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed. | 2011-12-01 |
20110293608 | ANNEXIN A2 AS IMMUNOLOGICAL TARGET - AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition. | 2011-12-01 |
20110293609 | Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity - The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity. | 2011-12-01 |
20110293610 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 2011-12-01 |
20110293611 | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade - Compositions and methods are provided for transplantation of pluripotent stem cells and differentiated cells derived therefrom. | 2011-12-01 |
20110293612 | Method for the Treatment of Neurodegenerative Diseases - Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L. | 2011-12-01 |
20110293613 | BISPECIFIC ANTIBODIES - The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2011-12-01 |
20110293614 | ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES - Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed. | 2011-12-01 |
20110293615 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor - The object of the present invention is to find a pharmaceutical composition and a method for treating cancer that show an excellent antitumor effect. Combinational use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogues thereof can result in an excellent antitumor effect when combined with a substance having a c-kit kinase-inhibiting activity. | 2011-12-01 |
20110293616 | Antigen-presenting complex-binding compositions and uses thereof - A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed. | 2011-12-01 |
20110293617 | ANTI-P-SELECTIN ANTIBODIES AND METHODS OF THEIR USE AND IDENTIFICATION - Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed. | 2011-12-01 |
20110293618 | ANTI-HUMAN CLCP1 ANTIBODY AND USE THEREOF - The present invention provides novel antibodies that recognize the extracellular domain of a human CLCP1 antigen; nucleic acids encoding the antibodies; vectors carrying the nucleic acids in an expressible manner; transformed cells containing the vectors; methods for producing the antibodies; diagnostic methods for cancer or prognosis of cancer, immunohistological or immunocytological assay methods, and kits for determining the expression level of CLCP1 in cells or tissues, all of which use the antibodies; pharmaceutical compositions comprising the antibodies; agents for treating or preventing CLCP1-expressing cancer; agents for inhibiting growth, migration, invasion, or metastasis of CLCP1-expressing cancer cells; immunostaining agents for staining CLCP1-expressing cancer cells; and agents for treating or preventing CLCP1-expressing tumor. The present invention also provides methods of screening for candidate substances that inhibit cancer cell growth, invasion, migration, or metastasis, or candidate substances having cytotoxicity against cancer cells. | 2011-12-01 |
20110293619 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain anti-body molecule. | 2011-12-01 |
20110293620 | Monoclonal Antibodies For Use In Diagnosis and Therapy of Cancers and Autoimmune Disease - The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-I in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided. | 2011-12-01 |
20110293621 | IMMUNOGENIC POLYPEPTIDES COMPRISING A SCAFFOLD POLYPEPTIDE AND A L2 POLYPEPTIDE OR A FRAGMENT THEREOF - The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method. | 2011-12-01 |
20110293622 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 2011-12-01 |
20110293623 | ANTIBODIES AS T CELL RECEPTOR MIMICS, METHODS OF PRODUCTION AND USES THEREOF - The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest. An effective amount of the immunogen is then administered to a host for eliciting an immune response, and serum collected from the host is assayed to determine if desired antibodies that recognize a three-dimensional presentation of the peptide in the binding groove of the MHC molecule are being produced. The desired antibodies can differentiate the peptide/MHC complex from the MHC molecule alone, the peptide alone, and a complex of MHC and irrelevant peptide. Finally, the desired antibodies are isolated. | 2011-12-01 |
20110293624 | Genes of an Otitis Media Isolate of NonTypeable Haemophilus Influenzae - The invention relates to the polynucleotide sequence of a nontypeable stain of | 2011-12-01 |
20110293625 | INHIBITION OF VEGF-A SECRETION, ANGIOGENESIS AND/OR NEOANGIOGENESIS BY SINA MEDIATED KNOCKDOWN OF VEGF-C AND RHOA - The invention relates to the use of short interfering nucleic acid molecules (siNAs, such as siRNAs) that modulate the expression of VEGF-C and/or RhoA involved in neovascular angiogenesis. In the present invention, inhibition of VEGF-C and/or RhoA gene expression lead to decreased expression of VEGF-A, which is required for initiation and the sustaining of angiogenesis. Further, the invention also relates to the inhibition of RhoA expression levels along with VEGF-C, so as to derive the benefits of down-regulating two different targets required for angiogenesis. The present invention describes compounds, compositions and methods useful for inhibition of neoangiogenesis. In certain embodiments, the invention relates to methods for inhibiting neovascularization, as well as compounds, such as VEGF-C and RhoA siRNAs, useful in the treatment of ocular disorders such as age related maculardegeneration (AMD), diabetic retinopathy, glaucoma and other neovascular disorders. | 2011-12-01 |
20110293626 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 2011-12-01 |
20110293627 | COMBINATION THERAPY TO ENHANCE NK CELL MEDIATED CYTOTOXICITY - The function of natural killer (NK) cells is regulated by inhibitory and activating signals delivered by cell surface receptors, 1-7F9 is a fully human monoclonal antibody (mAb) directed against KIR2DL1 and KIR2DL2/3 receptors that block its interaction with its HLA-C ligands breaking NK cell tolerance to autologous tumor cells. Lenalidomide has been shown to increase NK cell cytotoxicity in vitro. The combination of lenalidomide and 1-7F9 enhanced NK cell mediated cytotoxicity against U266 cells beyond that observed with each agent alone. Lenalidomide also increased the expression of NKG2D, DNAM-I and TRAIL ligands including: MICA, ULB P2, CD1 12 and DR 4 on U266 cells. In in vitro cytotoxicity assays, lenalidomide enhanced the susceptibility of myeloma cell lines to NK cell. The NK cell signaling pathways was also explored after lenalidomide treatment and the results show that lenalidomide may upregulate the phospho-SHIP1 (Tyr1020) and has no effect on phosphop44/42 (ERK 1/2) (Thr202/Tyr204) in NK cells. These results provide pre-clinical rationale for clinical investigation of 1-7F9 anti-KIR mAb and lenalidomide in MM. | 2011-12-01 |
20110293628 | PAIN TREATMENT USING ERK2 INHIBITORS - This application describes methods and compositions for reducing, inhibiting and/or treating pain that involve use of ERK2 inhibitors. | 2011-12-01 |
20110293629 | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists - The invention relates generally to methods of treating and/or preventing proliferative diseases, such as cancers, using antagonists of IL-17. The invention also relates to methods and kits for identifying subjects who are likely to respond to treatment and/or prevention of proliferative diseases with antagonists of IL-17. | 2011-12-01 |
20110293630 | Antibodies to Human GDF8 - The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8. | 2011-12-01 |
20110293631 | MAST CELL MARKERS AND PREVENTION, DIAGNOSIS, AND THERAPY FOR CHRONIC PELVIC PAIN SYNDROME - The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e g inhibition of MCP-1 and/or MIP-1α) to treat or prevent chronic pelvic pain syndrome. | 2011-12-01 |
20110293632 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 2011-12-01 |
20110293633 | PREPARATION USEFUL FOR, AND METHOD FOR TREATMENT OF NEONATAL ALLOIMMUNE THROMBOCYTOPENIC PURPURA (NAIT) - A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA | 2011-12-01 |
20110293634 | ANTIBODIES BINDING TO ADRENOMEDULLIN RECEPTORS AND USES THEREOF AS DRUGS - The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug. | 2011-12-01 |
20110293635 | COMPOSITION AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR ACTIVITY - The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression of Toll-like Receptor 14 interaction with CD14 during Toll-like Receptor mediated signalling. The invention further provides screening assays to identify compounds which have utility in preventing the association of Toll-like Receptor 14 and CD14. | 2011-12-01 |
20110293636 | Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer. | 2011-12-01 |
20110293637 | COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS - The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses. | 2011-12-01 |
20110293638 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 2011-12-01 |
20110293639 | IDEOTYPICALLY MODULATED PHARMACOEFFECTORS FOR SELECTIVE CELL TREATMENT - In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research. | 2011-12-01 |
20110293640 | Cholinesterase Inhibitors for Treating Inflammation - A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine. | 2011-12-01 |
20110293641 | A VACCINIA VIRUS PROTEIN A46 PEPTIDE AND USE THEREOF - A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide. | 2011-12-01 |